| dc.creator |
Wu, Yajun |
|
| dc.creator |
Wang, Yao |
|
| dc.creator |
Liu, Dongmin |
|
| dc.date |
2023-02-10T14:41:18Z |
|
| dc.date |
2023-02-10T14:41:18Z |
|
| dc.date |
2023-01-21 |
|
| dc.date |
2023-02-10T14:28:21Z |
|
| dc.date.accessioned |
2023-03-01T18:52:15Z |
|
| dc.date.available |
2023-03-01T18:52:15Z |
|
| dc.identifier |
Wu, Y.; Wang, Y.; Liu, D. Identification of Genipin as a Potential Treatment for Type 2 Diabetes. Int. J. Mol. Sci. 2023, 24, 2131. |
|
| dc.identifier |
http://hdl.handle.net/10919/113770 |
|
| dc.identifier |
https://doi.org/10.3390/ijms24032131 |
|
| dc.identifier.uri |
http://localhost:8080/xmlui/handle/CUHPOERS/281601 |
|
| dc.description |
The prevalence of type 2 diabetes (T2D) has been rising dramatically in many countries around the world. The main signatures of T2D are insulin resistance and dysfunction of β-cells. While there are several pharmaceutical therapies for T2D, no effective treatment is available for reversing the functional decline of pancreatic β-cells in T2D patients. It has been well recognized that glucagon-like peptide-1 (GLP-1), which is an incretin hormone secreted from intestinal L-cells, plays a vital role in regulating glycemic homeostasis via potentiating glucose-stimulated insulin secretion and promoting β-cell function. We found that genipin, a natural compound from Elli, can directly target intestinal L-cells, leading to the secretion of GLP-1. Incubation of the cells with genipin elicited a rapid increase in intracellular Ca<sup>2+</sup>. Inhibition of PLC ablated genipin-stimulated Ca<sup>2+</sup> increase and GLP-1 secretion, suggesting that genipin-induced GLP-1 release from cells is dependent on the PLC/Ca<sup>2+</sup> pathway. In vivo, acute administration of genipin stimulated GLP-1 secretion in mice. Chronically, treatment with genipin via oral gavage at 50 mg/kg/day for 6 weeks reversed hyperglycemia and insulin resistance in high-fat-diet (HFD)-induced obese mice. Moreover, genipin alleviated the impaired lipid metabolism and decreased lipid accumulation in the liver of obese mice. These results suggest that naturally occurring genipin might potentially be a novel agent for the treatment of T2D and diet-induced fatty liver disease. |
|
| dc.description |
Published version |
|
| dc.format |
application/pdf |
|
| dc.format |
application/pdf |
|
| dc.language |
en |
|
| dc.publisher |
MDPI |
|
| dc.rights |
Creative Commons Attribution 4.0 International |
|
| dc.rights |
http://creativecommons.org/licenses/by/4.0/ |
|
| dc.title |
Identification of Genipin as a Potential Treatment for Type 2 Diabetes |
|
| dc.title |
International Journal of Molecular Science |
|
| dc.type |
Article - Refereed |
|
| dc.type |
Text |
|